Veracyte to Participate in Upcoming Investor Conferences
Get Alerts VCYT Hot Sheet
Join SI Premium – FREE
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today it will participate in the following investor conferences.
-
Raymond James 47th Annual Institutional Investors Conference – Orlando, FL
Presentation on March 3rd at 8:05 a.m. Eastern Time -
Leerink Partners Global Health Conference – Miami, FL
Fireside chat on March 9th at 10:40 a.m. Eastern Time
Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. Replays of the webcasts will be available for 90 days after each live presentation broadcast.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).
View source version on businesswire.com: https://www.businesswire.com/news/home/20260219711059/en/
Investors:
Shayla Gorman
[email protected]
Media:
Molly Cornbleet
[email protected]
Source: Veracyte, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fishing history delivers Schmitt's third Bassmaster Elite title at Lake Champlain
- HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Can
- Solana Price Prediction: SOL Breaks $75 But the Real Entry Sits Inside Pepeto Before Listing
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Raymond James, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share